Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

British journal of haematology·2026
Same author

Molecular Relapse After a Second Treatment-Free Remission Attempt Following Asciminib in Chronic Myeloid Leukemia: A Case Report.

Case reports in hematology·2026
Same author

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Blood advances·2026
Same author

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Blood advances·2026
Same author

Risk Stratification of Non-Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation Based on Pre-Transplant Sarcopenia and HCT-CI.

Blood cell therapy·2026
Same author

Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan.

Blood neoplasia·2026

Related Experiment Video

Updated: Dec 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

920

Immune-Checkpoint Blockade Therapy in Lymphoma.

Ayumi Kuzume1,2, SungGi Chi1, Nobuhiko Yamauchi1

  • 1Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.

International Journal of Molecular Sciences
|August 6, 2020
PubMed
Summary

Immune-checkpoint blockade shows promise for treating lymphomas by blocking tumor evasion. While effective in Hodgkin lymphoma, its efficacy varies in non-Hodgkin lymphoma, necessitating further research.

Keywords:
hematologic malignanciesimmunotherapyprogrammed cell-death protein 1 (PD-1)

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.5K

Related Experiment Videos

Last Updated: Dec 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

920
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.5K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Tumor cells exploit immune-checkpoint pathways, expressing PD-L1/PD-L2 to suppress T-cell function and evade immune detection.
  • Programmed cell-death protein 1 (PD-1) on T cells binds PD-L1/PD-L2, inhibiting cytotoxicity and causing T-cell exhaustion.

Purpose of the Study:

  • To review the biology of immune-checkpoint inhibition.
  • To evaluate the efficacy of immune-checkpoint blockade in malignant lymphoma.
  • To identify patient subgroups benefiting most from this therapy.

Main Methods:

  • Literature review of clinical trials and biological mechanisms.
  • Analysis of response rates in Hodgkin and non-Hodgkin lymphoma patients treated with immune-checkpoint inhibitors.

Main Results:

  • Immune-checkpoint blockade is a potential therapeutic strategy for solid tumors and lymphomas.
  • Response rates in Hodgkin lymphoma range from 65% to 75%.
  • Lower response rates were observed in non-Hodgkin lymphoma compared to Hodgkin lymphoma.

Conclusions:

  • Immune-checkpoint blockade demonstrates significant efficacy in certain lymphomas, particularly Hodgkin lymphoma.
  • Further investigation is needed to optimize treatment strategies for non-Hodgkin lymphoma.
  • Understanding patient-specific factors is crucial for maximizing the effectiveness of immune-checkpoint inhibitors.